These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort. Friedman ND; Athan E; Walton AL; O'Brien DP Antimicrob Agents Chemother; 2016 May; 60(5):2692-5. PubMed ID: 26883709 [TBL] [Abstract][Full Text] [Related]
11. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844 [TBL] [Abstract][Full Text] [Related]
12. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. Friedman ND; Athan E; Hughes AJ; Khajehnoori M; McDonald A; Callan P; Rahdon R; O'Brien DP PLoS Negl Trop Dis; 2013; 7(7):e2315. PubMed ID: 23875050 [TBL] [Abstract][Full Text] [Related]
13. Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan. Sugawara M; Ishii N; Nakanaga K; Suzuki K; Umebayashi Y; Makigami K; Aihara M J Dermatol; 2015 Jun; 42(6):588-95. PubMed ID: 25809502 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy. Klis S; Kingma RA; Tuah W; van der Werf TS; Stienstra Y Trop Med Int Health; 2016 Sep; 21(9):1191-6. PubMed ID: 27456068 [TBL] [Abstract][Full Text] [Related]
16. Pharmacologic management of Van Der Werf TS; Barogui YT; Converse PJ; Phillips RO; Stienstra Y Expert Rev Clin Pharmacol; 2020 Apr; 13(4):391-401. PubMed ID: 32310683 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model. Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518 [TBL] [Abstract][Full Text] [Related]
18. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473 [TBL] [Abstract][Full Text] [Related]
19. [Bifocal Buruli ulcer: multiple cephalic lesions after initiation of medical treatment]. Vagamon B; Ahogo KC; Aka BR; Diabaté A; Kouassi YI; Kourouma SH; Traoré C; Gue I; Yoboue P; Kanga JM; Taieb A Ann Dermatol Venereol; 2013 Feb; 140(2):125-8. PubMed ID: 23395495 [TBL] [Abstract][Full Text] [Related]
20. Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions. Gyamfi E; Narh CA; Quaye C; Abbass A; Dzudzor B; Mosi L BMC Microbiol; 2021 Jan; 21(1):4. PubMed ID: 33402095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]